Merck Mumps Vaccine Antitrust Litigation
In re Merck Mumps Vaccine Antitrust Litigation, 13-cv-03555 (E.D. Pa.)
Robins Kaplan serves as court-appointed co-lead counsel on behalf of a proposed class of direct purchasers of the mumps vaccine from Merck. Plaintiffs allege that Merck unlawfully monopolized the U.S. market by engaging in a decade-long scheme to exclude competing manufacturers from the U.S. market. Plaintiffs allege that Merck did so in part by falsely claiming that its vaccine had an efficacy rate of 95% or higher, thus “raising the bar” for any competitor to match that efficacy rate and receive regulatory approval. Plaintiffs defeated Merck’s motion to dismiss and in July 2019, the court granted Plaintiffs’ motion to strike two former FDA officials that Merck retained as fact witnesses. The case is ongoing.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.